Rare diseases
Investigational molecules
Locations
Pneumococcal Polysaccharide Serotype 18C is a purified capsular polysaccharide from the bacterium Streptococcus pneumoniae, chemically linked (conjugated) to a tetanus toxoid carrier protein and adsorbed on aluminium phosphate. In the CTIS product records, it is part of Synflorix, a pneumococcal polysaccharide conjugate vaccine (adsorbed) supplied as a suspension for injection in pre-filled syringes.[1] Synflorix is authorised as a medicine in the European Union, with authorisation records including EU/1/09/508/002 through EU/1/09/508/005, and the authorisation holder is GlaxoSmithKline Biologicals S.A.[1] The NHS dm+d browser classifies the vaccine under ATC code J07AL02, the code for pneumococcal purified polysaccharides conjugated vaccines.[2]
Pneumococcal conjugate vaccines work by presenting bacterial polysaccharides attached to a carrier protein to the immune system. The polysaccharide alone is poorly recognised by the immature immune system of infants, but when conjugated to a carrier protein such as tetanus toxoid, it triggers a stronger, T-cell dependent antibody response. The antibodies produced against the serotype 18C polysaccharide help protect against invasive pneumococcal disease caused by that serotype.[2] In the Synflorix product records, serotype 18C is conjugated to tetanus toxoid carrier protein, while other serotypes in the same vaccine are conjugated to protein D derived from non-typeable Haemophilus influenzae or to diphtheria toxoid.[1]
Synflorix, the vaccine containing serotype 18C, is a suspension for injection given by intramuscular use in a 0.5 ml dose, supplied in pre-filled syringes.[1][2] The NHS dm+d browser records the formulation as a suspension for injection with a unit dose of 0.5 ml in pre-filled disposable syringes, with packs of 1 or 10 syringes.[2] In the Phase 2 trial, the monovalent candidate containing serotype 18C was administered as a 2-dose series by intramuscular injection to children aged 11 to 15 months.[1]
One completed Phase 2 trial (2023-505154-18-00) evaluated a monovalent pneumococcal conjugate candidate in healthy toddlers.[1] The trial enrolled 100 participants aged between 11 and 15 months and tested the candidate as a 2-dose series. The primary outcomes were prompted local reactions (redness, swelling and pain at the injection site), prompted systemic events (fever, decreased appetite, drowsiness or increased sleep, and irritability), adverse events and serious adverse events. The trial also compared the candidate against Synflorix and another investigational product, PF-07831695. The study is completed, meaning data collection has finished.[1]
The Phase 2 trial measured safety outcomes including local reactions at the injection site such as redness, swelling and pain, and systemic events such as fever, decreased appetite, drowsiness and irritability.[1] The Medscape review notes that pneumococcal serotypes differ in their potential for colonisation, invasiveness and virulence; serotypes with low invasive potential, such as types 3, 6A, 6B, 8, 19F and 23F, behave as opportunistic pathogens in at-risk individuals, while serotypes with high invasive potential, such as types 1 and 7F, can act as primary pathogens in previously healthy individuals.[3] The supplementary sources provided do not include a full product information list of side effects for Synflorix.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
